351 related articles for article (PubMed ID: 28502672)
1. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
2. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
3. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
4. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
5. Dual targeting of microtubule and topoisomerase II by α-carboline derivative YCH337 for tumor proliferation and growth inhibition.
Yi JM; Zhang XF; Huan XJ; Song SS; Wang W; Tian QT; Sun YM; Chen Y; Ding J; Wang YQ; Yang CH; Miao ZH
Oncotarget; 2015 Apr; 6(11):8960-73. PubMed ID: 25840421
[TBL] [Abstract][Full Text] [Related]
6. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
7. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
Nathwani SM; Butler S; Fayne D; McGovern NN; Sarkadi B; Meegan MJ; Lloyd DG; Campiani G; Lawler M; Williams DC; Zisterer DM
Cancer Chemother Pharmacol; 2010 Aug; 66(3):585-96. PubMed ID: 20020128
[TBL] [Abstract][Full Text] [Related]
8. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
Meng F; Cai X; Duan J; Matteucci MG; Hart CP
Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
Tripathi S; Srivastava G; Sharma A
Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
[TBL] [Abstract][Full Text] [Related]
10. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
11. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
12. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
[TBL] [Abstract][Full Text] [Related]
13. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
[TBL] [Abstract][Full Text] [Related]
14. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
[TBL] [Abstract][Full Text] [Related]
15. 4(1H)-quinolone derivatives overcome acquired resistance to anti-microtubule agents by targeting the colchicine site of β-tubulin.
Lin MS; Hong TM; Chou TH; Yang SC; Chung WC; Weng CW; Tsai ML; Cheng TR; Chen JJW; Lee TC; Wong CH; Chein RJ; Yang PC
Eur J Med Chem; 2019 Nov; 181():111584. PubMed ID: 31419740
[TBL] [Abstract][Full Text] [Related]
16. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells.
Lee WH; Liu HE; Chang JY; Liou JP; Huang HM
Pharmacology; 2013; 92(1-2):90-8. PubMed ID: 23949011
[TBL] [Abstract][Full Text] [Related]
17. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
[TBL] [Abstract][Full Text] [Related]
19. The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in β-tubulin.
Yang J; Yan W; Yu Y; Wang Y; Yang T; Xue L; Yuan X; Long C; Liu Z; Chen X; Hu M; Zheng L; Qiu Q; Pei H; Li D; Wang F; Bai P; Wen J; Ye H; Chen L
J Biol Chem; 2018 Jun; 293(24):9461-9472. PubMed ID: 29691282
[TBL] [Abstract][Full Text] [Related]
20. High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.
Pera B; Calvo-Vidal MN; Ambati S; Jordi M; Kahn A; Díaz JF; Fang W; Altmann KH; Cerchietti L; Moore MAS
Cancer Lett; 2015 Nov; 368(1):97-104. PubMed ID: 26277539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]